Proficiency and Knowledge of Community Pharmacists in the Use of Liraglutide and Semaglutide as Weight Reduction Agents
DOI:
https://doi.org/10.54133/ajms.v6i1.413Keywords:
Community Pharmacists, Knowledge, Liraglutide, Practice, Semaglutide, Weight-reduction agentsAbstract
Background: In recent years, the prevalence of obesity has climbed sharply. Still, only a few safe and effective medications are approved as weight-loss drugs. Objective: This study aims to assess the knowledge and practice of community pharmacists in Iraq regarding the use of Liraglutide and Semaglutide as weight-loss medications. Method: A cross-sectional survey was implemented using a validated questionnaire and a convenient sample of Iraqi community pharmacists from different governorates. The questionnaire was created after conducting a literature review of the most important articles about liraglutide and semaglutide. The questionnaire consists of three sections. The first part was used to collect demographic information. The second and third parts assessed community pharmacists' knowledge and practice of the anti-diabetic weight-loss agents Liraglutide and Semaglutide, respectively. Results: A total of 225 community pharmacists participated in this survey. The mean number of successfully answered knowledge questions by all participants was 15 out of 20, indicating a good knowledge of the Iraqi community pharmacists regarding using Liraglutide and Semaglutide as weight-loss medications. The current study revealed that the mean score for the practice section is 3.97, indicating that the participating pharmacists have good practice regarding using these medications. Conclusions: Community pharmacists have demonstrated adequate knowledge about correct administration escalation, storage, adverse effects, and other aspects of using Liraglutide and Semaglutide for weight loss. There is a knowledge gap between younger and older pharmacists.
Downloads
References
Higbea AM, Duval C, Chastain LM, Chae J. Weight effects of antidiabetic agents. Expert Rev Endocrinol Metab. 2017;12(6):441-449. doi: 10.1080/17446651.2017.1395694.
Phillips A, Clements JN. Clinical review of subcutaneous semaglutide for obesity. J Clin Pharm Ther. 2022;47(2):184-193. doi: 10.1111/jcpt.13574.
Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One. 2015;10(6):e0126769. doi: 10.1371/journal.pone.0126769.
Lavernia F, Blonde L. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgrad Med. 2020;132(sup2):15-25. doi: 10.1080/00325481.2020.1798638.
Zacks Equity Research. Novo Nordisk’s Rybelsus Gets EU Nod for Type II Diabetes | Nasdaq [Internet]. [cited 2022 Dec 24].
Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, et al. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Specialt Pharm. 2022;28(7):740-752. doi: 10.18553/jmcp.2022.28.7.740.
Um IS, Armour C, Krass I, Gill T, Chaar BB. Weight management in community pharmacy: what do the experts think? Int J Clin Pharm. 2013;35:447-454. doi: 10.1007/s11096-013-9761-4.
Eades CE, Ferguson JS, O'Carroll RE. Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health. 2011;11:1-3. doi: 10.1186/1471-2458-11-582.
Bain A, Kavanagh S, McCarthy S, Babar ZU. Assessment of insulin-related knowledge among healthcare professionals in a large teaching hospital in the United Kingdom. Pharmacy. 2019;7(1):16. doi: 10.3390/pharmacy7010016
Lee MK, Liu Z, Quek TP, Chew DE. Insulin-related knowledge among health care professionals at a tertiary hospital. Diabetes Spectrum. 2013;26(3):187-193. doi: 10.2337/diaspect.26.3.187.
Alshahrani SM. Assessment of knowledge, attitudes, and practice of community pharmacists regarding weight reduction agents and supplements in aseer region, Saudi Arabia. Risk Manag Healthcare Policy. 2020:347-353. doi: 10.2147/RMHP.S234818.
Balasanthiran A, Munro N, Watters K, Poots AJ, Morganstein D, Feher MD. Liraglutide withdrawal rates: Real world practice. Pract Diabetes. 2012;29(4):144-146. doi: 10.1002/pdi.1680.
U.S Food and Drug Administration. FDA approves new drug treatment for chronic weight management [Internet]. FDA Drug Safety Communication. 2022 [cited 2023 Apr 2].
Anonymous. Liraglutide for type 2 diabetes? Drug Ther Bull. 2010;48:50-53. doi: 10.1136/dtb.2010.01.0006.
Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity. 2020;28(6):1050-1061. doi: 10.1002/oby.22794.
Mirabelli M, Chiefari E, Caroleo P, Arcidiacono B, Corigliano DM, Giuliano S, et al. Long-term effectiveness of liraglutide for weight management and glycemic control in type 2 diabetes. Int J Environ Res Public Health. 2020;17(1):207. doi: 10.3390/ijerph17010207.
Mohammed SI, Dawood EB, Abaas IS. Perceptions and attitudes of community pharmacists towards patient counseling and continuing pharmacy education programs in Iraq. Iraqi J Pharm Sci. 2019;28(2):30-36. doi: 10.31351/vol28iss2pp30-36.
Selvadurai S, Cheah KY, Ching MW, Kamaruddin H, Lee XY, Ngajidin RM, et al. Impact of pharmacist insulin injection re-education on glycemic control among type II diabetic patients in primary health clinics. Saudi Pharm J. 2021;29(7):670-676. doi: 10.1016/j.jsps.2021.04.028.
Research C for DE. FDA approves weight management drug for patients aged 12 and older [Internet]. FDA. 2021 [cited 2023 Apr 2].
Mishore KM, Mekuria AN, Tola A, Ayele Y. Assessment of knowledge and attitude among pharmacists toward pharmaceutical care in eastern Ethiopia. BioMed Res Int. 2020;2020. doi: 10.1155/2020/7657625.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 )
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Published by Al-Rafidain University College. This is an open access journal issued under the CC BY-NC-SA 4.0 license (https://creativecommons.org/licenses/by-nc-sa/4.0/).
